• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Advances in predicting acute GVHD.急性移植物抗宿主病预测的研究进展。
Br J Haematol. 2013 Feb;160(3):288-302. doi: 10.1111/bjh.12142. Epub 2012 Dec 4.
2
Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?细胞因子在急性移植物抗宿主病(GVHD)发病机制中的作用:血清/血浆细胞因子是否为异基因造血细胞移植(Allo-HCT)后诊断急性 GVHD 的潜在生物标志物?
Curr Stem Cell Res Ther. 2012 May;7(3):229-39. doi: 10.2174/157488812799859856.
3
Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.肿瘤致瘤性2早期抑制对异基因干细胞移植后急性移植物抗宿主病及移植相关并发症的预测价值:前瞻性观察研究
Turk J Haematol. 2020 Feb 20;37(1):20-29. doi: 10.4274/tjh.galenos.2019.2019.0139. Epub 2019 Aug 29.
4
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
5
Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.造血干细胞移植患儿移植物抗宿主病发病时的血浆3型 pentraxin 水平可预测疾病严重程度及对治疗的反应。
Oncotarget. 2016 Dec 13;7(50):82123-82138. doi: 10.18632/oncotarget.13488.
6
Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.KIR基因型的供受者匹配可减少慢性移植物抗宿主病,且缺乏抑制性KIR配体可预防清髓性、HLA匹配的造血细胞移植后的复发。
PLoS One. 2016 Jun 24;11(6):e0158242. doi: 10.1371/journal.pone.0158242. eCollection 2016.
7
Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.移植物抗宿主病的预测:基于淋巴细胞和细胞因子的生物标志物组合
Ann Hematol. 2017 Jul;96(7):1127-1133. doi: 10.1007/s00277-017-2999-5. Epub 2017 Apr 26.
8
Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation.维生素 E 与骨髓清除性异基因造血细胞移植后急性移植物抗宿主病。
Eur J Haematol. 2021 Mar;106(3):417-424. doi: 10.1111/ejh.13567. Epub 2020 Dec 19.
9
Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.异基因造血干细胞移植后移植物抗宿主病对急性髓系白血病的影响:来自欧洲血液和骨髓移植组急性白血病工作组的报告。
Leukemia. 2012 Dec;26(12):2462-8. doi: 10.1038/leu.2012.135. Epub 2012 May 22.
10
Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.非清髓性造血干细胞移植中急性黏膜皮肤移植物抗宿主病的组织学评估及一项预测进展为慢性移植物抗宿主病风险增加的观察结果。
Am J Dermatopathol. 2007 Feb;29(1):1-6. doi: 10.1097/01.dad.0000246173.96318.0c.

引用本文的文献

1
Interleukin Networks in GVHD: Mechanistic Crosstalk, Therapeutic Targeting, and Emerging Paradigms.移植物抗宿主病中的白细胞介素网络:机制性相互作用、治疗靶点及新出现的模式
Int J Mol Sci. 2025 Sep 4;26(17):8620. doi: 10.3390/ijms26178620.
2
Monocytes as an early risk factor for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.单核细胞作为异基因造血干细胞移植后急性移植物抗宿主病的早期危险因素。
Front Immunol. 2024 Sep 12;15:1433091. doi: 10.3389/fimmu.2024.1433091. eCollection 2024.
3
Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell Transplantation.利用靶向转录组学和机器学习分析移植前后骨髓样本预测异基因干细胞移植后的急性移植物抗宿主病和总生存期
Cancers (Basel). 2024 Mar 29;16(7):1357. doi: 10.3390/cancers16071357.
4
Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?移植物抗宿主病:生物标志物能否辅助鉴别诊断、预后评估及治疗策略制定?
Pharmaceuticals (Basel). 2024 Feb 26;17(3):298. doi: 10.3390/ph17030298.
5
Assessment of risk factors for acute graft--host disease post-hematopoietic stem cell transplantation: a retrospective study based on a proportional odds model using a nonlinear mixed-effects model.造血干细胞移植后急性移植物抗宿主病危险因素的评估:一项基于比例优势模型并使用非线性混合效应模型的回顾性研究
Ther Adv Hematol. 2023 Oct 21;14:20406207231205406. doi: 10.1177/20406207231205406. eCollection 2023.
6
Impact of total marrow/lymphoid irradiation dose to the intestine on graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for hematologic malignancies.全骨髓/淋巴组织照射剂量对肠道的影响在血液系统恶性肿瘤异基因造血干细胞移植中对移植物抗宿主病的作用
Front Oncol. 2022 Dec 8;12:1035375. doi: 10.3389/fonc.2022.1035375. eCollection 2022.
7
A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.一项在同种异体造血细胞移植后,加用标准治疗预防移植物抗宿主病的前瞻性、随机、开放性标签的 II 期研究,评估添加去纤维肽的疗效。
Haematologica. 2023 Apr 1;108(4):1026-1038. doi: 10.3324/haematol.2022.281471.
8
Roles of the intestinal microbiota and microbial metabolites in acute GVHD.肠道微生物群和微生物代谢产物在急性移植物抗宿主病中的作用。
Exp Hematol Oncol. 2021 Oct 27;10(1):49. doi: 10.1186/s40164-021-00240-3.
9
Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2).利用细胞因子白细胞介素-33(IL-33)及其受体血清刺激因子2(ST2)预测异基因造血细胞移植后的免疫代谢并发症
Clin Hematol Int. 2020 May 21;2(3):101-108. doi: 10.2991/chi.d.200506.002. eCollection 2020 Sep.
10
Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective-A Literature Review.从支持性和姑息治疗角度看重度移植物抗宿主病患者的负担与需求——一项文献综述
Cancers (Basel). 2021 May 30;13(11):2697. doi: 10.3390/cancers13112697.

本文引用的文献

1
The WAP protein Trappin-2/Elafin: a handyman in the regulation of inflammatory and immune responses.WAP 蛋白 Trappin-2/Elafin:炎症和免疫反应调控中的多面手。
Int J Biochem Cell Biol. 2012 Aug;44(8):1377-80. doi: 10.1016/j.biocel.2012.05.007. Epub 2012 May 23.
2
Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia.高危急性髓系白血病成人患者中,亲缘不全相合/单倍体相合供者与无关供者异基因造血干细胞移植的比较。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1552-63. doi: 10.1016/j.bbmt.2012.04.008. Epub 2012 Apr 16.
3
TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.依那西普预防高危造血干细胞移植中移植物抗宿主病:肿瘤坏死因子受体 1 水平越低,结局越好。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1525-32. doi: 10.1016/j.bbmt.2012.03.013. Epub 2012 Mar 30.
4
Homeostatic maintenance of T cells and natural killer cells.T 细胞和自然杀伤细胞的稳态维持。
Cell Mol Life Sci. 2012 May;69(10):1597-608. doi: 10.1007/s00018-012-0968-7. Epub 2012 Mar 30.
5
Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.治疗期间测量的急性移植物抗宿主病生物标志物可预测治疗结局:一项血液和骨髓移植临床试验网络研究。
Blood. 2012 Apr 19;119(16):3854-60. doi: 10.1182/blood-2012-01-403063. Epub 2012 Mar 1.
6
Back to the future: mismatched unrelated donor, haploidentical related donor, or unrelated umbilical cord blood transplantation?回到未来:不匹配的无关供者、单倍体相合相关供者还是无关脐血移植?
Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S161-5. doi: 10.1016/j.bbmt.2011.11.004.
7
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.造血细胞移植后急性移植物抗宿主病的危险因素和生存情况。
Blood. 2012 Jan 5;119(1):296-307. doi: 10.1182/blood-2011-06-364265. Epub 2011 Oct 18.
8
Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis.供受者 HLA-A、B、C、DRB1 匹配对白血病和骨髓增生异常综合征患者脐血移植后结局的影响:一项回顾性分析。
Lancet Oncol. 2011 Dec;12(13):1214-21. doi: 10.1016/S1470-2045(11)70260-1. Epub 2011 Oct 6.
9
Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.胰岛衍生 3α 是胃肠道移植物抗宿主病的生物标志物。
Blood. 2011 Dec 15;118(25):6702-8. doi: 10.1182/blood-2011-08-375006. Epub 2011 Oct 6.
10
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.比较清髓性预处理与降低毒性预处理和脐血移植在儿科受者中免疫重建和移植物抗宿主病的情况。
Br J Haematol. 2011 Oct;155(2):218-34. doi: 10.1111/j.1365-2141.2011.08822.x. Epub 2011 Aug 16.

急性移植物抗宿主病预测的研究进展。

Advances in predicting acute GVHD.

机构信息

Blood and Marrow Transplant Program, Department of Pediatrics, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI 48109, USA.

出版信息

Br J Haematol. 2013 Feb;160(3):288-302. doi: 10.1111/bjh.12142. Epub 2012 Dec 4.

DOI:10.1111/bjh.12142
PMID:23205489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3552019/
Abstract

Acute graft-versus-host disease (GVHD) is a leading cause of non-relapse mortality following allogeneic haematopoietic cell transplantation. Attempts to improve treatment response in clinically-established GVHD have not improved overall survival, often due to the increased risk of infectious complications. Alternative approaches to decrease GVHD-related morbidity and mortality have focused on the ability to predict GVHD prior to clinical manifestation in an effort to provide an opportunity to abort GVHD development, and to gain new insights into GVHD pathophysiology. This review outlines the research efforts to date that have identified clinical and laboratory-based factors that are predictive of acute GVHD and describes future directions in developing algorithms that will improve the ability to predict the development of clinically relevant GVHD.

摘要

急性移植物抗宿主病(GVHD)是异基因造血细胞移植后非复发死亡的主要原因。尽管尝试改善临床确诊的 GVHD 治疗反应,但并未改善总体生存率,这通常是由于感染并发症风险增加所致。减少 GVHD 相关发病率和死亡率的替代方法侧重于在临床症状出现之前预测 GVHD 的能力,以提供中止 GVHD 发展的机会,并深入了解 GVHD 病理生理学。本综述概述了迄今为止确定可预测急性 GVHD 的临床和实验室因素的研究工作,并描述了开发算法以提高预测临床相关 GVHD 发展能力的未来方向。